2-Amino-6-merkaptopurin en es it fr

2-Amino-6-merkaptopurin Brand names, 2-Amino-6-merkaptopurin Analogs

2-Amino-6-merkaptopurin Brand Names Mixture

  • No information avaliable

2-Amino-6-merkaptopurin Chemical_Formula


2-Amino-6-merkaptopurin RX_link


2-Amino-6-merkaptopurin fda sheet

2-Amino-6-merkaptopurin FDA

2-Amino-6-merkaptopurin msds (material safety sheet)

2-Amino-6-merkaptopurin MSDS

2-Amino-6-merkaptopurin Synthesis Reference

Elion et al.; J.Amer.Chem.Soc.; 81;1898,1901 (1959)

2-Amino-6-merkaptopurin Molecular Weight

167.193 g/mol

2-Amino-6-merkaptopurin Melting Point

>360 oC

2-Amino-6-merkaptopurin H2O Solubility

36.3 mg/mL

2-Amino-6-merkaptopurin State


2-Amino-6-merkaptopurin LogP


2-Amino-6-merkaptopurin Dosage Forms

Oral tablets

2-Amino-6-merkaptopurin Indication

For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.

2-Amino-6-merkaptopurin Pharmacology

Thioguanine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute nonlymphocytic leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Thioguanine was first synthesized and entered into clinical trial more than 30 years ago. It is a 6-thiopurine analogue of the naturally occurring purine bases hypoxanthine and guanine. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Thioguanine is cross-resistant with mercaptopurine. Cytotoxicity is cell cycle phase-specific (S-phase).

2-Amino-6-merkaptopurin Absorption

Absorption of an oral dose is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%)

2-Amino-6-merkaptopurin side effects and Toxicity

Oral, mouse: LD50 = 160 mg/kg. Symptoms of overdose include nausea, vomiting, malaise, hypotension, and diaphoresis.

2-Amino-6-merkaptopurin Patient Information


Patients should be informed that the major toxicities of thioguanine are related to
myelosuppression, hepatotoxicity, and gastrointestinal toxicity. Patients should never
be allowed to take the drug without medical supervision and should be advised to consult
their physician if they experience fever, sore throat, jaundice, nausea, vomiting, signs
of local infection, bleeding from any site, or symptoms suggestive of anemia. Women of
childbearing potential should be advised to avoid becoming pregnant.

2-Amino-6-merkaptopurin Organisms Affected

Humans and other mammals